Secretoneurin, (SN) is a small 33-amino acid neuropeptide detectable in the blood stream and produced by neuroendocrine and heart muscle cells.

The use of SN for CVD is based on research carried out by world leading cardiac authorities at Akershus University Hospital, Oslo University Hospital and Akademiska Sjukhuset in Uppsala, Sweden. Patents have been granted in the US and Europe.

SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte Ca2+ handling (1). This unique biological function explains why SN is an independent and strong predictor of mortality in major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis.

SN is thus addressing a vast and untapped market potential for CVD patient diagnosis, risk stratification and monitoring, complementary to BNP/NT-proBNP and cardiac troponins.

Projects (pipeline):

Supported by funding from the Norwegian Research Council, and recently from EU’s Eurostars program, CardiNor’s short-term focus will be on the development of a sensitive and easy to use test for measuring SN in blood.

The current technology available for measuring SN is a RIA (radioimmunoassay) not suitable for routine or clinical use. We are developing a new test based on ELISA technology that is very well established in both clinical research and routine and can easily be adopted on high-throughput platforms such as Cobas by Roche and Architect by Abbott.

CardiNor has teamed up with several leading technology partners to secure access to world leading expertise and know-how vital for a successful assay development. These companies constitute our Eurostars team:

  • Bioventix UK on antibody development and production
  • Kaivogen Finland on assay development and production
  • Akershus University hospital on clinical validation

We also have access to world leading expertise on CVD biomarkers. Combined this provides CardiNor with a complete value chain from basic R&D through to production of final product.

This development will include validation using clinical cohort of 500 ICD patients (patients with an implanted cardiac defibrillator) to document its clinical utility in patients with arrhythmia in accordance with the In Vitro Diagnostic Directive (IVDD) leading to CE marking.

Key Publications:

Prognostic Value of Secretoneurin in Patients With Severe Sepsis and Septic Shock: Data From the Albumin Italian Outcome Sepsis Study.

Røsjø H, Masson S, Caironi P, Stridsberg M, Magnoli M, Christensen G, Moise G, Urbano MC, Gattinoni L, Pesenti A, Latini R, Omland T; ALBIOS Biomarkers Study Investigators.

Crit Care Med. 2018 May;46(5)

Prognostic Value of Secretoneurin in Patients with Acute Respiratory Failure: Data from the FINNALI Study.

Myhre PL, Ottesen AH, Okkonen M, Linko R, Stridsberg M, Nygård S, Christensen G, Pettilä V, Omland T, Røsjø H; FINNALI Laboratory Study Group.

Clin Chem. 2016 Oct;62(10):1380-9.

Prognostic Value of Secretoneurin in Critically Ill Patients with Infections.

Røsjø H, Stridsberg M, Ottesen AH, Nygård S, Christensen G, Pettilä V, Linko R, Karlsson S, Varpula T, Ruokonen E, Omland T; FINNSEPSIS and FINNALI Study Groups.

Crit Care Med. 2016 Oct;44(10):1882-90.

Will secretoneurin be the next big thing?

Anderson ME.

J Am Coll Cardiol. 2015 Feb 3;65(4):352-4.

Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling.

Ottesen AH, Louch WE, Carlson CR, Landsverk OJ, Kurola J, Johansen RF, Moe MK, Aronsen JM, Høiseth AD, Jarstadmarken H, Nygård S, Bjørås M, Sjaastad I, Pettilä V, Stridsberg M, Omland T, Christensen G, Røsjø H.

J Am Coll Cardiol. 2015 Feb 3;65(4):339-51.

Secretogranin II; a protein increased in the myocardium and circulation in heart failure with cardioprotective properties.

Røsjø H, Stridsberg M, Florholmen G, Stensløkken KO, Ottesen AH, Sjaastad I, Husberg C, Dahl MB, Øie E, Louch WE, Omland T, Christensen G.

PLoS One. 2012;7(5): e37401. Epub 2012 May 24.


Arrhythmia: An irregular heartbeat that is either abnormally slow (bradycardia) or too fast (tachycardia).

Biomarker: Generally refers to a measurable indicator of some biological state or condition. Biomarkers are often measured and evaluated to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

Cardiac arrest: When the heart stops beating suddenly and respiration (breathing) and other body functions cease as a result. Without immediate treatment, the affected person will die.

Cardiac resynchronization therapy (CRT): Implantable device therapy for people with moderate to severe heart failure who also have ventricular desynchrony. Helps the lower chambers of the heart (left and right ventricles) beat together in a normal rhythm again.

Coronary artery disease: Chronic condition in which a clogged artery prevents the heart from receiving sufficient blood.

Echocardiogram (or «echo»): A cardiac imaging test that provides information concerning the anatomy and function of the heart, including a measurement of how well the heart is pumping (ejection fraction or EF, see below).

Ejection fraction (EF): The percentage of blood pumped by the left ventricle during every heartbeat. People with a normal, healthy heart typically have an ejection fraction of 55 percent or greater. An ejection fraction of 40 percent or less indicates a weakened heart.

Electrocardiogram (ECG): A test that records the electrical activity of the heart, revealing evidence of previous heart attacks, enlargement of the heart and abnormal rhythms.

Enzyme-linked immunosorbent assay (ELISA): A test that uses antibodies and color change to identify a substance, e.g. in a blood sample. ELISA is often used as a diagnostic tool in medicine.

Implantable cardio-verter defibrillator (ICD): A surgically inserted electronic device that constantly monitors your heart rate and rhythm. When it detects a very fast, abnormal heart rhythm, it can deliver a rapid electrical pule or if required an electrical shock to the heart muscle to restore normal rhythm.

Pacemaker: A small electronic device implanted under the skin activated by a slow heart rate. If required, the pacemaker will send electrical impulses to the heart muscle in order to maintain a normal heart rate.

Ventricular fibrillation (VF): A abnormally rapid heart rhythm disorder originating in the ventricles that is unstable and irregular. Electronic signals move through the heart erratically and prevent it from beating properly causing circulatory collapse. Untreated, VF will cause sudden cardiac death.

Ventricular tachycardia (VT): A heart rhythm disorder originating in the ventricles. Rapid contractions prevent the heart from filling adequately with blood between beats. Patient may become dizzy, faint or collapse. Can be life threatening if not treated.

Contact Us

Send us an email and we'll get back to you, asap.